4.5 Letter

Blinatumomab-induced lineage switch of B-ALL with t(4:11) (q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

Related references

Note: Only part of the references are listed.
Letter Oncology

The possible perils of targeted therapy

U. Duffner et al.

LEUKEMIA (2016)

Article Oncology

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

Ahmad Rayes et al.

PEDIATRIC BLOOD & CANCER (2016)

Article Oncology

The MLL recombinome of acute leukemias in 2013

C. Meyer et al.

LEUKEMIA (2013)

Article Medicine, General & Internal

Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia

Martin Schrappe et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)